Table 1 Baseline characteristics of study participants
Baseline characteristics | 3-dose group (n = 27) | 4-dose group (n = 27) | p-value |
|---|---|---|---|
Age, years (mean ± SD) | 45.8 ± 13.5 | 46.6 ± 11.0 | 0.826 |
Male | 16 (59.3%) | 16 (59.3%) | 1.000 |
Risk of HIV acquisition | 0.487 | ||
 Heterosexual | 19 (70.4%) | 21 (77.8%) |  |
 Homosexual (MSM) | 7 (25.9%) | 5 (18.5%) |  |
 Blood transfusion | 1 (3.7%) | 0 |  |
 IVDU | 0 | 1 (3.7%) |  |
Time since HIV diagnosis, years (mean ± SD) | 12.4 ± 6.2 | 11.3 ± 6.4 | 0.534 |
Duration of cART, years (mean ± SD) | 10.0 ± 4.8 | 9.4 ± 4.7 | 0.691 |
CD4+ cell count, cells/mm3 (median (IQR) | 611 (429, 853) | 534 (392, 829) | 0.697 |
Nadir CD4+ cell count, cells/mm3 (median (IQR) | 148 (52, 323) | 110 (52, 228) | 0.392 |
Nadir CD4+ cell count < 200 cells/mm3 | 19 (70.4%) | 18 (66.7%) | 0.770 |
Current cART active against HBV | 27 (100%) | 27 (100%) | Â |
cART regimen | 1.000 | ||
 NNRTI-based | 25 (92.6%) | 25 (92.6%) |  |
 PI-based | 2 (7.4%) | 2 (7.4%) |  |
NRTI/NtRTI backbone | 1.000 | ||
 TDF/FTC | 24 (88.9%) | 23 (85.2%) |  |
 TDF + 3TC | 1 (3.7%) | 1 (3.7%) |  |
 AZT/3TC | 1 (3.7%) | 2 (7.4%) |  |
 ABC/3TC | 1 (3.7%) | 1 (3.7%) |  |